Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer

Published:2024-07 Issue:7 Volume:42 Page:1286-1300.e8
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Zhou Caicun^ORCID,Li Chongyang,Luo Libo,Li Xin,Jia Keyi,He Ning,Mao Shiqi,Wang Wanying,Shao Chuchu,Liu Xinyu,Huang Kan,Yu Yaxin,Cai Xinlei,Chen Yingxue,Dai Zican,Li Wei,Yu Jia,Li Jiayu,Shen Feng,Wang Zaiyong,He Feng,Sun Xing,Mao Rongfu,Shi Wei,Zhang Jun,Jiang Tao,Zhang Zhe,Li Fei,Ren Shengxiang

Publisher

Elsevier BV

Reference56 articles.

1. Next batter up! Targeting cancers with KRAS-G12D mutations;Zeissig;Trends Cancer,2023

2. Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer;Fell;J. Med. Chem.,2020

3. Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors;Lanman;J. Med. Chem.,2020

4. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor;Hallin;Nat. Med.,2022

5. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor;Wang;J. Med. Chem.,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cell death pathways: molecular mechanisms and therapeutic targets for cancer;MedComm;2024-09

2. HRS-4642: The next piece of the puzzle to keep KRAS in check;Cancer Cell;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP